Semaglutide or tirzepitide is approved for adults with type 2 diabetes and obesity and may also be prescribed for individuals without diabetes who have obesity or overweight along with other weight-related medical conditions
An article outlining the effectiveness of GLP-1RAs on obesity
Mitranun W, Deerochanawong C, Tanaka H, Suksom D
Balancing sensitivity, selectivity, and robustness across the full peptide lifecycle remains a key challenge
Until then the peptide problem is growing and changing every day and it likely will remain one of the biggest challenges for retailers, anti-doping authorities, government regulators, the medical community, and consumer safety advocates to address over the next decade or more
Lancet 366 , 12671278 (2005)